Company Overview and News

 
Kesoram Industries Limited - Appointment

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
502937 KESORAMIND KRIDF

 
Kesoram Industries Limited - Resignation

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
502937 KESORAMIND KRIDF

3
JSW Steel hits 52-week high, Lupin falls 2% after NSE announces rejig of Nifty

2018-08-29 moneycontrol
Shares of Lupin down 2 percent, while JSW Steel touched 52-week high of Rs 379.50, rising more than 3 percent after National Stock Exchange (NSE) announced fresh Nifty rejig effective from September 28.
PWQFY KESORAMIND 500228 BHUSANSTL 533096 532418 532955 MARKSANS 533155 532810 JUBLFOOD ABAN CMQMY 532461 ENGINERSIN JBLWY 532480 CUMMINSIND 500055 502937 524404 ALNSE ALBK JSWSTEEL 532401 VIJAYABANK BRK.A PFC 532178 500480 PNJZY PNB 534809 ADANIPOWER PCJEWELLER RECLTD 523204 KRIDF ANDHRABANK

 
Kesoram Industries Limited - Financial Result Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
502937 KESORAMIND KRIDF

 
Kesoram Industries Limited - News Clarification

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
502937 KESORAMIND KRIDF

 
Kesoram Industries Limited - Shareholders meeting

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
502937 KESORAMIND KRIDF

 
Kesoram Industries Limited - Shareholders meeting

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
502937 KESORAMIND KRIDF

 
Kesoram Industries scouting for partner for loss-making tyres biz

2018-07-13 moneycontrol
Kesoram Industries Limited, a B K Birla group company, is on the lookout for a partner for its loss-making tyres business, a company official today said.
502937 KESORAMIND KRIDF

 
US-China trade war tensions to take centre stage in coming week; These 3 stocks to be in focus

2018-07-08 moneycontrol
The upcoming week will be important for the market as developments around imposition of US-China tariffs are likely to stay in focus through the week.
BAJAJ-AUTO KESORAMIND SHALPAINTS 532418 KTKBANK 532218 532977 SOUTHBANK 532187 INOXWIND HEROMOTOCO 500231 502937 INDUSINDBK VTUWY 533269 500182 532652 532210 ONP UMANGDAIR CUB HRTQY 539083 509874 KRIDF WABAG ANDHRABANK

 
Kesoram Industries Limited - Appointment

2018-05-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
502937 KESORAMIND KRIDF

 
Kesoram Industries Limited - Allotment of Securities

2018-04-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
502937 KESORAMIND KRIDF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...